Skip to main content
Top
Published in: Current Hematologic Malignancy Reports 4/2011

01-12-2011 | Intermediate- and High-Grade Non-Hodgkin Lymphoma (Andre Goy, Section Editor)

Update: Peripheral T-Cell Lymphomas

Author: Kerry J. Savage

Published in: Current Hematologic Malignancy Reports | Issue 4/2011

Login to get access

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of biologically heterogeneous but typically aggressive diseases. Progress in understanding and developing optimal therapies for PTCLs has been hampered by disease rarity and only relatively recent recognition of the importance of the T-cell phenotype. The International Peripheral T-cell Lymphoma Project was a large collaborative effort to provide a broader understanding of prognosis. Recently, several new therapies have shown promise in the treatment of PTCLs.
Literature
1.
go back to reference Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.PubMed Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.PubMed
2.
go back to reference Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
3.
go back to reference International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.CrossRef International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.CrossRef
4.
go back to reference Dupuis J, Emile J, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108:4163–9.PubMedCrossRef Dupuis J, Emile J, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108:4163–9.PubMedCrossRef
5.
go back to reference •• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–8. This evaluation of prognostic factors in PTCL-NOS comes from the International Peripheral T-Cell Lymphoma Project. PubMedCrossRef •• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–8. This evaluation of prognostic factors in PTCL-NOS comes from the International Peripheral T-Cell Lymphoma Project. PubMedCrossRef
6.
go back to reference Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164(5):1837–48.PubMedCrossRef Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164(5):1837–48.PubMedCrossRef
7.
go back to reference Thorns C, Bastian B, Pinkel D, et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer. 2007;46(1):37–44.PubMedCrossRef Thorns C, Bastian B, Pinkel D, et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer. 2007;46(1):37–44.PubMedCrossRef
8.
go back to reference de Leval L, Gaulard P. Pathology and biology of peripheral T-cell lymphomas. Histopathology. 2011;58(1):49–68.PubMedCrossRef de Leval L, Gaulard P. Pathology and biology of peripheral T-cell lymphomas. Histopathology. 2011;58(1):49–68.PubMedCrossRef
9.
go back to reference Ballester B, Gisselbrecht C, Gaulard P, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Ann Oncol. 2005;16(Supp 5):124a. Ballester B, Gisselbrecht C, Gaulard P, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Ann Oncol. 2005;16(Supp 5):124a.
10.
go back to reference •• Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–36. This gene expression profiling study with a focus on AILT identifies molecular signatures associated with a favorable or unfavorable prognosis. PubMedCrossRef •• Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–36. This gene expression profiling study with a focus on AILT identifies molecular signatures associated with a favorable or unfavorable prognosis. PubMedCrossRef
11.
go back to reference de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63.PubMedCrossRef de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63.PubMedCrossRef
12.
go back to reference Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–75.PubMedCrossRef Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–75.PubMedCrossRef
13.
go back to reference Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9.PubMedCrossRef Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9.PubMedCrossRef
14.
go back to reference Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111(9):4463–70.PubMedCrossRef Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111(9):4463–70.PubMedCrossRef
15.
go back to reference Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;1994:1281–4.CrossRef Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;1994:1281–4.CrossRef
16.
go back to reference Mason D, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (“Ki-1 lymphoma”) are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74:161–8.PubMedCrossRef Mason D, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (“Ki-1 lymphoma”) are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74:161–8.PubMedCrossRef
17.
go back to reference Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156–64.PubMedCrossRef Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156–64.PubMedCrossRef
18.
go back to reference Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA. 2010;107(37):16228–33.PubMedCrossRef Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA. 2010;107(37):16228–33.PubMedCrossRef
19.
go back to reference • Sibon D, Fournier M, Briere J, et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d’Etude Des Lymphomes De l’Adulte (GELA). Blood (ASH Annual Meeting Abstracts). 2010;116(21):322. This large study of ALCL patients identified the importance of age as well as ALK status for prognosis. • Sibon D, Fournier M, Briere J, et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d’Etude Des Lymphomes De l’Adulte (GELA). Blood (ASH Annual Meeting Abstracts). 2010;116(21):322. This large study of ALCL patients identified the importance of age as well as ALK status for prognosis.
20.
go back to reference Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104(10):3358–60.PubMedCrossRef Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104(10):3358–60.PubMedCrossRef
21.
go back to reference Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516–26.PubMedCrossRef Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516–26.PubMedCrossRef
22.
go back to reference • Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915–9. This article reports on a novel technique to discover recurrent translocation in ALK-negative ALCL. PubMedCrossRef • Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915–9. This article reports on a novel technique to discover recurrent translocation in ALK-negative ALCL. PubMedCrossRef
23.
go back to reference Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596–605.PubMedCrossRef Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596–605.PubMedCrossRef
24.
go back to reference ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43(5):462–9.PubMedCrossRef ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43(5):462–9.PubMedCrossRef
25.
go back to reference Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96(9):2993–3000.PubMed Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96(9):2993–3000.PubMed
26.
go back to reference Gascoyne R, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–21.PubMed Gascoyne R, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–21.PubMed
27.
go back to reference • Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. This is a detailed study from the International Peripheral T-Cell Lymphoma Project regarding ALCL. PubMedCrossRef • Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. This is a detailed study from the International Peripheral T-Cell Lymphoma Project regarding ALCL. PubMedCrossRef
28.
go back to reference Popplewell L, Thomas SH, Huang Q, et al. Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma. 2011;52(8):1481–7.PubMedCrossRef Popplewell L, Thomas SH, Huang Q, et al. Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma. 2011;52(8):1481–7.PubMedCrossRef
29.
go back to reference Lazzeri D, Agostini T, Bocci G, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer. 2011 May 11 (Epub ahead of print). Lazzeri D, Agostini T, Bocci G, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer. 2011 May 11 (Epub ahead of print).
30.
go back to reference Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011 May 12 (Epub ahead of print). Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011 May 12 (Epub ahead of print).
31.
go back to reference Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–6.PubMedCrossRef Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–6.PubMedCrossRef
32.
go back to reference Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145(2):173–9.PubMedCrossRef Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145(2):173–9.PubMedCrossRef
33.
go back to reference Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–66.PubMedCrossRef Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–66.PubMedCrossRef
34.
go back to reference • Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25. This is a retrospective analysis of prospective studies evaluating the impact of etoposide on the outcome of PTCL. PubMedCrossRef • Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25. This is a retrospective analysis of prospective studies evaluating the impact of etoposide on the outcome of PTCL. PubMedCrossRef
35.
go back to reference Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1595–600.PubMedCrossRef Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1595–600.PubMedCrossRef
36.
go back to reference Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.PubMedCrossRef Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.PubMedCrossRef
37.
go back to reference Foss FM, Sjak-Shie A, Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial. J Clin Oncol. 2010;28(15s):8045a. Foss FM, Sjak-Shie A, Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial. J Clin Oncol. 2010;28(15s):8045a.
38.
go back to reference Corazzelli G, Frigeri F, Marcacci G, et al. Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell/NK lymphomas: a phase II trial. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2829. Corazzelli G, Frigeri F, Marcacci G, et al. Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell/NK lymphomas: a phase II trial. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2829.
39.
go back to reference Mahadevan D, Unger JM, Persky DO, et al. Phase II trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). Ann Oncol. 2011;22(Suppl 4 111a):5–282. Mahadevan D, Unger JM, Persky DO, et al. Phase II trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). Ann Oncol. 2011;22(Suppl 4 111a):5–282.
40.
go back to reference • Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–9. This is a report of a promising new L-asparaginase combination for extranodal NK/T-cell lymphoma. PubMedCrossRef • Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–9. This is a report of a promising new L-asparaginase combination for extranodal NK/T-cell lymphoma. PubMedCrossRef
41.
go back to reference Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103(10):2091–8.PubMedCrossRef Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103(10):2091–8.PubMedCrossRef
42.
go back to reference • d’Amore F, Relander T, Lauritzsen GF, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)—overall and subtype-specific results of a phase II study from Nordic Lymphoma Group. Haematologica. 2009;94(supplement 2):437. These are preliminary results of large phase II prospective study of ASCT in untreated PTCLs. • d’Amore F, Relander T, Lauritzsen GF, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)—overall and subtype-specific results of a phase II study from Nordic Lymphoma Group. Haematologica. 2009;94(supplement 2):437. These are preliminary results of large phase II prospective study of ASCT in untreated PTCLs.
43.
go back to reference Relander T, Lauritzsen GF, Jantunen E, et al. Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and Autologous Stem Cell Transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood (ASH Annual Meeting Abstracts). 2010;116(21):3566. Relander T, Lauritzsen GF, Jantunen E, et al. Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and Autologous Stem Cell Transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood (ASH Annual Meeting Abstracts). 2010;116(21):3566.
45.
go back to reference • Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26(14):2264–71. This is the largest study evaluating the outcome of PTCL patients treated with allogeneic transplantation. PubMedCrossRef • Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26(14):2264–71. This is the largest study evaluating the outcome of PTCL patients treated with allogeneic transplantation. PubMedCrossRef
46.
go back to reference Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22(7):1608–13.PubMedCrossRef Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22(7):1608–13.PubMedCrossRef
47.
go back to reference O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357–64.PubMedCrossRef O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357–64.PubMedCrossRef
48.
go back to reference • O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9. This is the first study evaluating a novel agent specifically in relapsed/refractory PTCL. PubMedCrossRef • O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9. This is the first study evaluating a novel agent specifically in relapsed/refractory PTCL. PubMedCrossRef
49.
go back to reference • Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34. This phase II study evaluates romidepsin in relapsed/refractory PTCL. PubMedCrossRef • Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34. This phase II study evaluates romidepsin in relapsed/refractory PTCL. PubMedCrossRef
50.
go back to reference Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) following prior systemic therapy. Blood (ASH Annual Meeting Abstracts). 2010;116(21):114. Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) following prior systemic therapy. Blood (ASH Annual Meeting Abstracts). 2010;116(21):114.
51.
go back to reference Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22):920. Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22):920.
52.
go back to reference Forero-Torres A, Bernstein S, Gopal A, et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood. 2004;104(11):2637. Forero-Torres A, Bernstein S, Gopal A, et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood. 2004;104(11):2637.
53.
go back to reference • Shustov A, Advani R, Brice P, et al. Durable remissions with SGN-et (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Ann Oncol. 2011;22(Supp 4):5–282. This phase II study evaluated brentuximab vedotin in relapsed/refractory ALCL. • Shustov A, Advani R, Brice P, et al. Durable remissions with SGN-et (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Ann Oncol. 2011;22(Supp 4):5–282. This phase II study evaluated brentuximab vedotin in relapsed/refractory ALCL.
54.
go back to reference Evens AM, Gordon LI, Patton D, et al. Phase I results of combination gemcitabine and bortezomib (Velcade(R)) for relapsed/refractory nodal T-cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL). Blood (ASH Annual Meeting Abstracts). 2008;112(11):2005. Evens AM, Gordon LI, Patton D, et al. Phase I results of combination gemcitabine and bortezomib (Velcade(R)) for relapsed/refractory nodal T-cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL). Blood (ASH Annual Meeting Abstracts). 2008;112(11):2005.
55.
go back to reference O’Connor OA. Novel agents in development for peripheral T-cell lymphoma. Semin Hematol. 2010;47 Suppl 1:S11–4.PubMedCrossRef O’Connor OA. Novel agents in development for peripheral T-cell lymphoma. Semin Hematol. 2010;47 Suppl 1:S11–4.PubMedCrossRef
56.
go back to reference Kim SJ, Eom H-S, Kim JS, et al. The efficacy of Bortezomib-CHOP in patients with advanced stage T or NK/T cell lymphomas: the results of multicenter phase II study [abstract]. ASH Annu Meet Abstracts. 2010;116(21):1791. Kim SJ, Eom H-S, Kim JS, et al. The efficacy of Bortezomib-CHOP in patients with advanced stage T or NK/T cell lymphomas: the results of multicenter phase II study [abstract]. ASH Annu Meet Abstracts. 2010;116(21):1791.
57.
go back to reference Delmer A, Fitoussi P, Gaulard P, et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05–1 T trial. J Clin Oncol. 2009;27(15S):8554a. Delmer A, Fitoussi P, Gaulard P, et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05–1 T trial. J Clin Oncol. 2009;27(15S):8554a.
58.
go back to reference Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116(19):4541–8.PubMedCrossRef Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116(19):4541–8.PubMedCrossRef
59.
go back to reference Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52(8):1585–8.PubMedCrossRef Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52(8):1585–8.PubMedCrossRef
60.
go back to reference O’Leary HM, Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep. 2009;4(4):227–35.PubMedCrossRef O’Leary HM, Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep. 2009;4(4):227–35.PubMedCrossRef
Metadata
Title
Update: Peripheral T-Cell Lymphomas
Author
Kerry J. Savage
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Hematologic Malignancy Reports / Issue 4/2011
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-011-0100-3

Other articles of this Issue 4/2011

Current Hematologic Malignancy Reports 4/2011 Go to the issue

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

Low-Grade Non-Hodgkin Lymphoma (Peter McLaughlin, Section Editor)

Recent Developments in Nongastric Mucosa-Associated Lymphoid Tissue Lymphoma

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

CD30+ Neoplasms of the Skin

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

PET in T-Cell Lymphoma

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.